Checkpoint Capital
Latest statistics and disclosures from Checkpoint Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ARGX, RYTM, PHAT, CYTK, AXSM, and represent 77.18% of Checkpoint Capital's stock portfolio.
- Added to shares of these 9 stocks: CYTK (+$15M), PHAT (+$11M), ARGX (+$5.6M), TCRX, STOK, SLNO, PLRX, IRON, CDTX.
- Started 3 new stock positions in STOK, IRON, TCRX.
- Reduced shares in these 9 stocks: RYTM (-$14M), CORT (-$8.0M), AXSM (-$7.3M), PTGX (-$5.2M), KYMR, APLT, TRVI, AVDL, ATYR.
- Sold out of its positions in APLT, CORT, KYMR.
- Checkpoint Capital was a net buyer of stock by $3.7M.
- Checkpoint Capital has $202M in assets under management (AUM), dropping by 21.52%.
- Central Index Key (CIK): 0001977548
Tip: Access up to 7 years of quarterly data
Positions held by Checkpoint Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Checkpoint Capital
Checkpoint Capital holds 16 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Argenx Se Sponsored Adr (ARGX) | 24.9 | $50M | +12% | 93k | 542.08 |
|
| Rhythm Pharmaceuticals (RYTM) | 17.2 | $35M | -28% | 663k | 52.39 |
|
| Phathom Pharmaceuticals (PHAT) | 13.5 | $27M | +71% | 1.5M | 18.08 |
|
| Cytokinetics Com New (CYTK) | 12.2 | $25M | +145% | 467k | 52.80 |
|
| Axsome Therapeutics (AXSM) | 9.3 | $19M | -27% | 210k | 89.87 |
|
| Avadel Pharmaceuticals Com Shs (AVDL) | 7.2 | $14M | -3% | 1.1M | 13.12 |
|
| Protagonist Therapeutics (PTGX) | 5.4 | $11M | -32% | 240k | 45.00 |
|
| Pliant Therapeutics (PLRX) | 2.1 | $4.3M | +63% | 380k | 11.21 |
|
| Tscan Therapeutics (TCRX) | 2.0 | $4.1M | NEW | 825k | 4.98 |
|
| Atyr Pharma Com New (ATYR) | 1.5 | $3.1M | -10% | 1.7M | 1.76 |
|
| Soleno Therapeutics (SLNO) | 1.5 | $2.9M | +194% | 58k | 50.49 |
|
| Cidara Therapeutics Com New (CDTX) | 1.0 | $2.0M | +25% | 182k | 10.75 |
|
| Stoke Therapeutics (STOK) | 1.0 | $1.9M | NEW | 158k | 12.29 |
|
| Disc Medicine (IRON) | 0.6 | $1.3M | NEW | 26k | 49.14 |
|
| Trevi Therapeutics (TRVI) | 0.4 | $835k | -50% | 250k | 3.34 |
|
| Allakos (ALLK) | 0.2 | $425k | 650k | 0.65 |
|
Past Filings by Checkpoint Capital
SEC 13F filings are viewable for Checkpoint Capital going back to 2023
- Checkpoint Capital 2024 Q3 filed Nov. 14, 2024
- Checkpoint Capital 2024 Q2 filed Aug. 14, 2024
- Checkpoint Capital 2024 Q1 filed May 15, 2024
- Checkpoint Capital 2023 Q4 filed Feb. 14, 2024